IGF-1 LR3

Growth hormone axisNot approved; research useBanned in sport (WADA)

Also known as: Long R3 IGF-1; approved relative: mecasermin

A long-acting modified IGF-1 used for muscle growth.

Educational reference, not medical advice. Many compounds here are not approved, and products sold as research chemicals are not checked for purity. Plan any use with a licensed clinician.

How it works

Binds the IGF-1 receptor directly, driving muscle protein synthesis and glucose uptake.

Evidence by goal

GoalGradeWhat the grade means
Muscle & growth hormoneDAnimal or cell studies only

At a glance

Route
Subcutaneous or intramuscular
Half-life
About 20 to 30 hours

Reported dosing

20 to 50 mcg daily (user reports).

Timing: After training.

Cycle: 4 weeks on, 4 off.

From approved labels where they exist, otherwise from published trials and practitioner reports.

Side effects

  • Low blood sugar (can be severe)
  • Joint pain, headache
  • Theoretical organ and tumor growth

Who should avoid it

  • Any cancer history
  • Diabetes medications
  • Pregnancy

Often combined with

Rarely combined; risk of hypoglycemia rises with other GH-axis compounds.

Key findings

No human trials for this analog. Mecasermin (Increlex) is approved for severe primary IGF-1 deficiency in children.

Where it is legal (Oct 2026)

USNot approved
CanadaNot approved
MexicoNot approved
EUNot approved

Sources

Open IGF-1 LR3 in the Peptide Guide Compare all peptides by goal

Last reviewed November 2026. Regulatory status reflects the US unless noted and changes often.

Natoorales and e4life.io (Mexico residency and immigration help) are sister businesses founded by Ian Kain.

Scroll to Top